

nuvo™

Give life
a better beginning™

TRANSFORMING PREGNANCY CARE THROUGH ML-DRIVEN REMOTE MONITORING

2025



DISCLAIMER

The information contained in this Investor Presentation is for informational purposes only and is not intended to serve as financial, legal, or investment advice. The content provided herein is based on current data and projections as of the date of publication and is subject to change without notice. This information may contain forward-looking statements, which include but are not limited to projections, plans, objectives, and future performance or assumptions underlying such statements. These statements are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied herein. Nuvo Intl Group Inc. does not guarantee the accuracy, completeness, or timeliness of the information provided and expressly disclaims any liability for errors or omissions. Certain information has been provided by third-party sources and, although believed to be reliable, it has not been independently verified, and its accuracy or completeness cannot be guaranteed. Past performance is not indicative of future results. Each investor should consult their own advisers regarding the legal, tax, and financial suitability of any type of investment. This information does not constitute an offer to sell or a solicitation to buy any securities or other financial instruments and is strictly confidential, intended only for the person to whom it has been delivered, and under no circumstance may a copy be shown, copied, transmitted, or otherwise given to any person other than the authorized recipient.

The reader agrees to the provisions set forth in the “Disclaimers” located at <https://www.finalis.com/disclaimers>. The terms thereof are incorporated by reference as though fully set forth herein. References therein to (i) 'Company' mean the entity involved in this transaction (together with its affiliates, subsidiaries, successors, and assigns); (ii) 'Banker' refers to the registered representative of Finalis Securities LLC involved in this transaction; and (iii) 'Bank' refers to Catalyst Capital Markets LLC. Securities are offered through Finalis Securities LLC, member FINRA/SIPC.

An investment in a private placement is highly speculative and involves a high degree of risk, including the potential loss of the entire investment.

Nuvo Investment Thesis

- Nuvo is the only FDA approved, CE mark company delivering self administered medical-grade NSTs at home accepted by OBs as a basis for monitoring the fetal health
 - A Non-Stress Test (NST) is a non-invasive procedure that monitors the baby's heart rate, and mother's contractions during the third trimester to confirm healthy growth and development. With an NST, any signs of distress can be identified early.
- The ability of doing NSTs at home allows the hospitals and OB clinics, to a) free up labor, as well as b) free up limited exam-room space for other revenue generating activities, while c) continuing to collect reimbursement for remote NSTs and d) improving patient safety and satisfaction scores
- ~62% of approx. 3.7M US pregnancies are considered high-risk, requiring at least once a week NST in the 3rd trimester
- In addition, maternity care “deserts” are growing across the country, with ~ 36% of the US counties lacking OB care today
- Resulting in a total addressable US market for Nuvo of ~\$5b, with a significant advantage over competitors protected by 10+ years and ~\$100M of R&D investments, and 20 patents
- Opportunity to invest at a significant discount to the valuation the company was trading at in public markets a year ago



INVU™ has been recognized as one of TIME's Best Inventions of 2024 in the Home Health category.

Nuvo pre-2025: A Strong Tech Platform

- Israeli-domiciled company
- 10+ years in research, innovation and clinical development
- FDA , EU CE and Israel regulatory approvals
- 1.5 years of commercial pilots completed, with 500+ patients, and 3,500+ remote check-ups
- World-class Board of Directors

With one mistake made

- Decided to go public via a SPAC in May 2024 at a pre-money valuation of \$300M
- SPAC sponsors and inside investors contributed capital to bridge between going public and follow-on offering, and F1 filed
- However, Nuvo's investment bank failed to execute the proposed follow-on to properly capitalize the company
- Resulting in Nuvo terminating the investment bank for cause, and needing to enter Ch 11 reorganization in 2H 2024
- Then CEO, with a storied healthcare pedigree, resigned after the asset purchase



INVU™ has been recognized as one of TIME's Best Inventions of 2024 in the Home Health category.

2025 Nuvo Intl:

Innovation with a Solid Commercial Plan

- Laurence Klein, co-founder and Board member, with a personal investment in Nuvo totaling ~\$6M, partnered with other former shareholders to purchase all the assets out of Ch 11 and reorganized the Company as a US –domiciled Delaware Corp, and began operating as of January 2025


Nuvo Now

- Has a clean balance sheet
- Has no financial legacies
- Has substantially lower overhead
- Expanding the Nuvo platform with additional AI/ML modules
- Is a global company, with customers in the US as well as Israel
- Focused on tangible market execution



INVU™ has been recognized as one of TIME's Best Inventions of 2024 in the Home Health category.

INVU BY NUVO™: ALL-IN-ONE ML PLATFORM FOR (REMOTE) PREGNANCY MONITORING



Pregnancy Care: Massive Problems / Nuvo Opportunity

~62% of pregnancies treated as high-risk¹: Chronic diseases and pregnancies later in life

Maternity care deserts* growing;
~36% of US counties lack OB care²

OB shortage expected to be 22,000 by 2050³

Healthcare consumerism
is increasing patient
expectations for care

3.66M
Annual U.S. Pregnancies⁴

\$100B+
Total US spend in pregnancy care⁵

High-Risk Market
62% Identified high-risk⁶ \$58B+ Annual US spend⁷

**Nuvo Opportunity to Improve
These Maternity Cost Centers**

\$1.5-\$3.2B
Scheduled
Outpatient NST¹¹

\$2.4B
Spontaneous
OB-ED¹⁰

\$24B
NICU
Admissions⁸

\$14B
Maternal Mood
and Anxiety
Disorders⁹

*Maternity care deserts are counties where there are no hospitals providing obstetric care, no birth centers, no OB/GYN and no certified nurse midwives.

Notes: 1) AJOG 2015, 2) March of Dimes 2022, 3) AJMC 2019, 4) CDC 2021 Vital Statistics Rapid Release, 5) NIH/AMIA data, 6) AJOG 2015, 7) JAMA 2020, 8) Journal of Pediatrics 2018, 9) Mathematica 2019, 10) AJOG 2017, 11) Contemporary OB/GYN 2015

FIRST GENERATION: INVU BY NUVO™

Remote Fetal Monitoring for Peace of Mind

1 Comfort and Ease at Home or Work:

A mother-to-be can now monitor the baby's health from the comfort of home, eliminating the need for stressful or frequent trips to the clinic

2 What is an NST?:

A Non-Stress Test (NST) is a simple, non-invasive procedure that monitors the baby's heart rate and mother's contractions during the third trimester to confirm healthy growth and development

3 Why is NST Important?:

By monitoring the baby's heart rate and contractions, an NST ensures any signs of distress are identified early



INVU by Nuvo™: A Technical Description

Leading-Edge, ML-Driven Remote Pregnancy Monitoring Platform

- 1 A wearable belt equipped with state-of-the-art patented sensors
- 2 Hardware collects acoustic, bio-potential, and movement signals
- 3 Maternal & Fetal phonocardiography (mPCG and fPCG), electrocardiogram (mECG and fECG), and Maternal Uterine Activity (MUA) are calculated and analyzed by the INVU™ Data Platform
- 4 MUA, along with Maternal and Fetal Heart Rates (MHR and FHR), is transmitted to the INVU™ Software Platforms

Leveraging Data for ML Advancement

Accumulated data is utilized to train ML models for future applications

A Market-Exclusive Technology

Nuvo™ is the only company delivering self administered medical grade NSTs accepted by OBs as a basis for monitoring the fetal health, based on a ML-driven platform



Biopotential
Signals



Acoustic
Signals



Movement
Signals



The INVU™ Data Platform: Powered by ML

- **Collecting Real-World Data**

Data is gathered from commercial and clinical settings to create valuable insights.

- **Transforming Data into Insights**


The platform uses AI to convert raw data into features like heart activity and health patterns.

- **Smarter Health Solutions**

AI analyzes data for personalized health monitoring and product improvements.

- **Improving Population Health**

Unified clinical and physiological data enables better health outcomes.



Proprietary hardware and cloud platform ensures that NUVO™ is the sole holder of critical data.

ROI Across the Healthcare Ecosystem

Private Clinics



- ✓ Patient satisfaction & convenience
- ✓ Improve staff efficiency & exam room utilization
- ✓ Competitive differentiation

- New revenue stream up to \$1,500 / patient
- Premium service differentiation
- ~1,800 US clinics / 1M+ patients

Fetal NST:

- Medically necessary protocol to monitor fetal health
- Guidelines call for twice weekly appointments for last 8 weeks of pregnancy¹

Payers

- ✓ OB-ED avoidance
- ✓ De-hospitalization reduction in cost of care
- ✓ Cost-effective coverage in care deserts

- Average savings/patient:
 - \$1K+ de-hospitalization
 - \$500+ OB-ED³
- 3.66M US annual pregnancies



Hospital Systems




- ✓ Improved staff efficiency
- ✓ Increased revenue potential
- ✓ Competitive differentiation

- Save ~\$22K in nurse time/year⁴
- Incremental annual rev potential/exam room = ~\$450K⁵
- 200+ US health systems / 4K+ hospitals

Employers

- ✓ Employee satisfaction & productivity
- ✓ Attracting & retaining talent
- ✓ Reducing total cost of care

- +20% productivity/pregnancy²
- System cost savings



1) ACOG fetal surveillance guidelines, 2) Nuvo estimates and ACOG fetal surveillance guidelines, 3) Nuvo estimates based on McMorries study and CDC 2021 Vital Statistics Rapid Release, UHG 2019 report and AJOG 2017, 4) Nuvo estimates and Zippia nurse salary report, 5) Nuvo estimates and MDSave OBGYN average patient visit.

Private Clinic ROI Case Study

Rural OB practice in Texas

Three primary challenges:

Maintaining Standard of Care

Twice weekly NST's was extremely difficult or impossible for most patients.

High no-show rates and/or patients late to appointments, backing up schedule.

Clinical Staff Workload

Significant portion of weekly nurse and other staff time spent on NST's

Patient Satisfaction

Patients challenged with extensive travel time, additional PTO taken, and childcare coordination just to attend medically necessary monitoring sessions.

NWC's Remote NST Benefits

5% **Increase in top line revenue** generated from in-office visits by opening appointment times for other patients who require in-person visits.

53% **Reduction in nurse time** spent on remote NSTs compared to in-office NSTs.

80 minutes In average **time saved for patients per appointment**, down from 105 minutes to just 25 minutes. This includes session time and driving time to/from NST.

80% Of patients were able to **conduct NSTs at work**, without taking time off.

12 hours Total patient **time saved on average** through utilization of remote NSTs.

<5% **No-show rate** as a result of adopting remote NSTs.

100% Of patients who experienced decreased fetal movement were able to **avoid a potential trip to the OB-ED** by undergoing NST triage from home instead.

From Providers



From Patients



Nuvo Unit Economics

Today



Per Pregnancy



Lifetime Value

Pregnancy Usage	3 rd Trimester	
# Pregnancies	1	12
Average Price	\$1,500	\$18,000
Refurb & Op Cost	\$150	\$1,800
Wearable Cost	\$1,000 / 12 = \$83	\$1,000
Gross Margin	\$1,267	\$15,200
Gross Margin %	84%	

Mass Market (~Y28)



Per Pregnancy



Lifetime Value

Pregnancy Usage	20+ Weeks	
# Pregnancies	1	12
Average Price	\$1,000	\$12,000
Refurb & Op Cost	\$75	\$900
Wearable Cost	\$900 / 12 = \$42	\$500
Gross Margin	\$883	\$10,600
Gross Margin %	88%	



Opportunity

3.66M
\$1,000
\$2 - \$3B

Frictionless Setup, Logistics, and Training



OB prescribes INVU™ Sensory Band, and blood pressure cuff



Nuvo ships INVU™ to patient




Patient downloads app and registers



Patient View
Patient views meaningful data in INVU™ app



Patient returns INVU™ at end of pregnancy



OB or MFM sees comprehensive data through **INVU™ Pro** dashboard
Clinician View

Remote monitoring sessions convenient for **Virtual Clinic Hours**

Patients Love the Convenience, Comfort & Peace of Mind



"I think the INVU belt is awesome! I like that I can just monitor myself at home ❤️"



"I think it's awesome this belt lets me stay home and monitor my baby by myself with no need to go back and forth for appointments."



"The convenience of being home and not having to get a sitter for my 5yr old is nice."



"Comfortable and easy, offers great peace of mind."

Nuvo Patient NPS Scores

66

NPS* score for patient onboarding satisfaction

67

NPS score for patient end of care satisfaction

Providers Love the Benefits & Practicality

“I’m excited to be able to offer INVU to our patients to reduce some of that burden, help address geographic and socioeconomic inequities, and enable us to maintain high quality care.”

“Patients won’t have to use PTO just to come here for her appt. Patients don’t have to take time off work, especially for those who are unable to take time off like teachers, healthcare workers; they can do these [NST] sessions at work.”

“It has been amazing! Huge impact on opening appts times for other patients. Allows patients more freedom and the opportunity to save PTO.”

“I thought it was easy and intuitive. No problems navigating. I have my nurse enroll the patient, but reading the NST’s and interpreting very easy.”

“Huge satisfier for patients.”

“The idea is to leverage AI to for earlier detection of signs of fetal suffering... Another aspect is preventing these pregnancy complications...”



Integrated IP Strategy as a Competitive Edge

Patent Stats by Family:

- Issued utility patents: 16 U.S. / 44 Outside U.S.
- Pending utility patent applications: 10 U.S. / 13 Outside U.S.
- Issued design patents: 3 U.S. / 7 Outside U.S.
- One PCT patent application

Key Portfolio Coverage Areas:

- Fetal Heart Rate (FHR) Detection
- MUA Detection
- Belt Design & Function
- Sensors
- Big Data
- **ML/AI Data-based Clinical Decision Support**

NUVO™'s intellectual property acts as a strategic safeguard, blocking competitors from penetrating its hardware, cloud, and data domains



Wearable Sensor Belt
Hardware and Sensors



INVU™
Data Platform



Data

Nuvo Featured in Journals & Publications

Highlight Reference

Better Compliance for High Risk Pregnancy

- Hybrid remote and in-clinic maternal-fetal surveillance for women with gestational diabetes: A prospective pilot study (International Journal of OBGYN 2025) <https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.16148>

>90% Efficacy Using INVU for Remote NST

- Use of a wireless monitoring device to perform nonstress tests from home: the patient perspective (AJOG 2024) - <https://www.sciencedirect.com/science/article/pii/S2589933324000685?dgcid=coauthor>

Confirming Usability of INVU For NST at Home

- Utilization of a wireless monitoring device to perform nonstress tests in high-risk pregnancies from home (AJOG 2023) - [https://www.ajog.org/article/S0002-9378\(23\)00381-2/fulltext](https://www.ajog.org/article/S0002-9378(23)00381-2/fulltext)

Banner Health Validation Of UPenn Study

- Letter to the AJOG editor from Banner Health - [https://www.ajog.org/article/S0002-9378\(23\)00809-8/fulltext](https://www.ajog.org/article/S0002-9378(23)00809-8/fulltext)

Validation that INVU Is More Accurate than TOCO

- A Novel, Cardiac-Derived Algorithm for Uterine Activity Monitoring in a Wearable Remote Device (Frontiers in Bioengineering & Biotechnology 2022) <https://www.frontiersin.org/articles/10.3389/fbioe.2022.933612/full>

Validation that INVU Is Effective for Self-Administered NST

- Novel uterine contraction monitoring to enable remote, self-administered nonstress testing (AJOG 2022) - [https://www.ajog.org/article/S0002-9378\(21\)01211-4/fulltext](https://www.ajog.org/article/S0002-9378(21)01211-4/fulltext)

Validation that INVU is Comparable to SoC for fHR

- Wireless, remote solution for home fetal and maternal heart rate monitoring (AJOG 2020) - [https://www.ajogmf.com/article/S2589-9333\(20\)30031-8/fulltext](https://www.ajogmf.com/article/S2589-9333(20)30031-8/fulltext)



Sheba & Nuvo: Developing the Future of Pregnancy Care

Groundbreaking agreement combining commercial use + ML/AI-driven research




Commercial Clinical Use Partner

- Global leader in remote pregnancy care
- INVU-based remote command & control center
- Remotely managing highest risk pregnancies
- Achieving better outcomes
- Providing convenience and comfort
- Discovering new insights

ML-Driven Research Partner


- Global leader in pregnancy research
- Leveraging ML-driven INVU-platform
- New discoveries being published
- Agreement to generate four ML-based modules for new pathways in pregnancy care





Clinical Studies Demonstrating Efficacy of Self-Administered NST Checkups Using INVU

- Two UPenn-based studies of INVU by Nuvo™
- Resulting in two medical posters presented at SMFM '22 and SMFM '25
- Y25 Poster demonstrates efficacy of conducting remote self-administered NSTs over 2,000 sessions
- Y22 poster demonstrates efficacy of using the INVU by Nuvo™ platform for CDSS (clinical decision support system)
- Y2025 poster results being submitted for publication in a peer reviewed medical journal



INVU-Based Studies to be Concluded and Published in Y25



Demonstrating the cost-effectiveness and benefits to patients, providers and payers of remote pregnancy care using INVU, with an emphasis on rural patients



Using fetal electrocardiogram (fECG) data with INVU to determine link with maternal stress and fetal brain development




Demonstrating the overall cost-effectiveness and benefits of remote pregnancy care using INVU (e.g. care compliance)



Demonstrating the cost-effectiveness and benefits of CDSS (clinical decision support system) using INVU for remote pregnancy care

Remote Pregnancy Monitoring: A Global Market Opportunity



Personal Nuvo Related References



Laurence Klein
CEO
Co-Founder and
Founding Investor

Strategic References



Deb Henretta
Independent Board Director
Former President P&G



Gerald Ostrov
Former Chairman & CEO of
Bausch + Lomb, Former
Group Chairman J&J

Medical References



Prof. Lawrence Platt, MD
Clinical Professor Dept of
Obstetrics & Gynecology
at UCLA
Founder of Center for Fetal
Medicine, LA



Dr. Nadav Schwartz, MD
Clinical Director of Outpatient
MFM Services at
University of Pennsylvania



Prof. Jack Rychik, MD
Director of the Fetal Heart
Program at CHOP



Dr. Avi Tsur, MD
Founder & Director of
Sheba Women's Health
Innovation Center

Current Cap Table


- Original Investors 43% Pref/\$3.6M
- Original Investors 52% Com
- Granted Options 5% Com
- Author. Options 20% Com

Use of Funds

- 40% Sales & Marketing
- 25% Development/Maintenance
- 10% Ops
- 5% Regulatory & Compliance
- 10% Public Market Readiness
- 10% Working Capital & Runway

Raise Summary

- Amount: \$3M
- Instrument: Pref Equity
- Pre-Money Valuation: \$15M
- 1st Closing : @\$1M
- Price Per Share: \$14
- Rights: Pre-emptive
anti-dilution



Contact Us

www.nuvocares.com

USA
2980 NE 207th St.
Aventura, FL
33180